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Abstract The N-glycans of recombinant proteins produced via
the secretory pathway of cultured mammalian cells are often
undersialylated, and insect cells lack sialytransferases. Under-
sialylated glycoproteins are rapidly cleared from the circulation,
compromising the effect of pharmaceuticals. We show that
incubation with living Saccharomyces cerevisiae cells expressing
the catalytic ectodomain of rat liver K2,3-sialyltransferase
(ST3Ne) in the porous cell wall resulted in sialylation of
glycoproteins. The Km values of the yeast enzyme for several
substrates were similar to those of recombinant ST3Ne from
insect cells and of authentic ST3N. The yeast strain provides an
inexpensive self-perpetuating source of ST3N activity for glycan
engineering of recombinant proteins.
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1. Introduction
Many mammalian pharmaceutical proteins manufactured
in cultured cells by gene technology are secretory proteins
with sialylated N-glycans. However, the recombinant proteins
are often undersialylated, even when produced in mammalian
cells, or sialylation is not authentic [1,2]. For instance cultured
CHO and BHK-21 cells lack a functional K2,6-sialyltransfer-
ase, whereas in human and mouse cells glycoproteins are sial-
ylated by both K2,3- and K2,6-linked residues [3,4]. Moreover,
the host cell may lack sialyltransferases, like yeast and insect
cells, or shed sialidase activity which desialylates the secreted
protein product [5]. Lack of sialylation increases dramatically
the plasma clearance rate of the proteins, compromising
severely the pharmaceutical e¡ect [6^10]. Clearance is accom-
plished by the hepatic asialoglycoprotein receptor, which rec-
ognizes terminal galactose residues of unsialylated N-glycans,
resulting in elimination of the glycoprotein-receptor complex
from the cell surface by endocytosis [11]. We show here that
undersialylated and unsialylated native glycoproteins can be
sialylated by incubation with living recombinant Saccharomy-
ces cerevisiae cells harboring rat liver K2,3-sialyltransferase
activity in the porous cell wall.
2. Materials and methods
2.1. Strains and media
S. cerevisiae strains H23 (MatK his3-11,15 leu2-3,112 trp1-1 ade2-1
can1-100 hsp150: :URA3) and H626 (MatK his3-11,15 leu2-3,112 ade2-
1 can1-100 hsp150: :URA3 TRP1: :HSP150v-ST3Ne) and Escherichia
coli DH5K were grown as described [12]. To fuse ST3Ne to the
Hsp150 signal peptide, the DNA encoding amino acids 29^374 of
ST3N was isolated from plasmid pKTH4638 (designated pKTH4636
in [12]), and inserted in plasmid pKTH4659 (Bluescript) between the
sequences encoding amino acids 1^18 of Hsp150 (signal peptide) and
the ADH1 terminator, creating pKTH4674. The HSP150SP-ST3Ne
fragment was ligated to the pFL35 shuttle vector resulting in plasmid
pKTH4675, which was linearized with EcoRV at the TRP1 locus and
transformed to strain H23 to create strain H771. The HSP150v-
ST3Ne and ST3Ne genes were driven by the HSP150 promoter [13].
2.2. Sialyltransferase assays
Duplicate samples of 5U107 yeast cells were incubated in 70 Wl of
50 mM imidazole bu¡er, pH 7.0 (glycoproteins), or of 50 mM Tris-
maleate bu¡er, pH 6.7 (oligosaccharides), either with 0.2 nmol (105
cpm) of CMP[14C]Neu5Ac (294 mCi/mmol, Amersham International,
Buckinghamshire, UK) or with saturating concentrations of CMP-
Neu5Ac (Sigma, St. Louis, MO, USA), and varying amounts of ac-
ceptor substrates, in a shaker at 24‡C. The cells were pelleted and the
supernatants subjected to precipitation with 20% TCA for 30 min on
ice. For determination of intracellular plus extracellular ST3N activ-
ity, the cells were lysed with glass beads [12]. Recombinant ST3Ne
(0.34 mU) produced in Sf9 cells (Calbiochem-Novabiochem, La Jolla,
CA, USA) was incubated at 37‡C in 20 Wl of 50 mM MOPS bu¡er,
pH 7.5, containing 1% BSA, and 0.06 nmol of CMP[14C]Neu5Ac
(28 500 cpm) or saturating concentrations of CMP-Neu5Ac, and dif-
ferent amounts of acceptors before TCA precipitation. Oligosaccha-
rides were applied on columns of Dowex AG 1 (acetate form, Bio-
Rad, Hercules, CA, USA) and Dowex 50 (H form, Fluka, Switzer-
land), which were eluted with 4 ml of water and then with 20 ml of 0.5
M acetic acid [14]. The test proteins were from Sigma (St. Louis, MO,
USA), except transferrin (Finnish Red Cross, Helsinki, Finland), and
prothrombin (ICN, Aurora, OH, USA). Desialylation was in 0.025 M
H2SO4 for 1 h at 80‡C [15].
2.3. Mass spectrometry and circular dichroism (CD) spectroscopy
Desialylated proteins were desalted on reversed-phase HPLC. The
N-glycans were liberated by N-glycosidase F digestion and puri¢ed
using Bond Elut C-18-columns [16]. Bu¡er salts were removed by
drop dialysis against water on VSWP 02500 membranes (Millipore,
Bedford, MA, USA) [17]. Matrix-assisted laser desorption/ionization
time-of-£ight (MALDI-TOF) mass spectrometry was performed on a
Bi£ex instrument (Bruker-Franzen Analytik, Bremen, Germany)
equipped with a nitrogen laser operating at 337 nm. Oligosaccharides
were analyzed with THAP matrix in the linear positive ion mode,
which causes little fragmentation of sialic acids [16]. CD spectroscopy
was performed using a Jasco J-720 spectropolarimeter. The spectra
were recorded in the far UV region (190^259 nm). Each spectrum was
the mean of ¢ve scans obtained with a time constant of 1 s and a
speed of 20 nm/min.
2.4. Kinetic studies
The Km determinations were according to Lineweaver-Burk. To
determine the activity of Hsp150v-ST3Ne, H626 cells (5U107) were
incubated with 0.4 mM lacto-N-tetraose and 10 mM CMP-Neu5Ac.
The supernatant was subjected to ion exchange chromatography over
the Dowex columns and the eluates were concentrated and chromato-
graphed on a Superdex7Peptide PC 3.2/30 column (Pharmacia, Swe-
den) [16]. The oligosaccharides were quantitated against external lac-
to-N-tetraose (Sigma) and NeuNAc (Sigma).
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3. Results
3.1. Transfer of [14C]Neu5Ac to N-glycans of
asialoglycoproteins
Sialyltransferases are type II transmembrane glycoproteins
of the Golgi membrane [18]. We have constructed a S. cere-
visiae strain, which expresses the ectodomain of rat liver K2,3-
sialyltransferase (ST3Ne) as a fusion protein Hsp150v-ST3Ne
[12]. The Hsp150v polypeptide promotes proper folding of
several foreign proteins in the yeast endoplasmic reticulum
(ER) [19,20]. Hsp150v-ST3Ne was transported to the yeast
cell wall to which it was tightly bound. Incubation of the yeast
cells with N-acetyllactosamine and CMP-Neu5Ac resulted in
K2,3-sialylation of the disaccharide, as shown by NMR spec-
troscopy [12].
Here we studied whether asialoglycoproteins could be sial-
ylated by the recombinant yeast cells. Bovine plasma fetuin
(MW 48 kDa) carries two triantennary and one biantennary
N-glycan, and three O-glycans, all completely sialylated
[21,22]. Fetuin was desialylated with mild acid hydrolysis
and incubated with CMP-[14C]Neu5Ac and yeast cells (strain
H626) expressing Hsp150v-ST3Ne in the cell wall. Sodium
azide was included to block intracellular protein transport.
Samples were removed at di¡erent times, the cells pelleted
and the supernatants subjected to precipitation with trichloro-
acetic acid (TCA). Scintillation counting showed that the pre-
cipitated radioactivity increased with time (Fig. 1A, closed
circles). It was con¢rmed by mass spectrometry to be fetuin
with covalently linked [14C]Neu5Ac residues (see below). Very
little radioactivity remained cell-associated, showing that the
sialylated protein and CMP-[14C]Neu5Ac did not adhere to
the cells. When desialylation was omitted (Fig. 1A, open
squares), or when asialofetuin was incubated with yeast cells
(H23) lacking the HSP150v-ST3Ne gene (open circles), no
radioactivity was bound to fetuin. Hsp150v-ST3Ne was spe-
ci¢c for N-glycans, since no [14C]Neu5Ac was transferred to
asialomucin, which carries only O-glycans (Fig. 1A, triangles).
Thus, asialofetuin could be sialylated by the cell wall-borne
Hsp150v-ST3Ne.
Sialylation of asialofetuin was enhanced when the incuba-
tion with H626 cells was carried out in the presence of dithio-
threitol (DTT) (Fig. 1B, closed squares). DTT increases the
porosity of the cell wall by reducing disul¢de bonds [23].
When Hsp150v-ST3Ne was allowed to be synthesized and
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Fig. 1. Transfer of [14C]Neu5Ac to asialofetuin and asialomucin by
whole yeast cells. A: H626 cells and CMP-[14C]Neu5Ac were incu-
bated with asialofetuin (closed circles), fetuin (open circles), or asia-
lomucin (triangles), and parental cells (H23) were incubated with
asialofetuin (open squares), all in the presence of 10 mM NaN3. B:
Asialofetuin was incubated as above with NaN3 (closed circles), or
with 40 mM DTT (closed squares), or with 4% glucose (open
circles), or with 4% glucose and 40 mM DTT (open squares). TCA-
precipitated radioactivity is plotted against incubation time.
Fig. 2. Relative ST3N activities in yeast cells expressing Hsp150v-
ST3Ne (H626) and ST3Ne (H771) using asialofetuin and CMP-
[14C]Neu5Ac as substrates. Black area: activity in cell wall. White
area: intracellular activity. Insert: Northern blot of strains H626
(lane 1), H771 (lane 2) and H23 (lane 3) probed with ST3Ne
cDNA. Size markers (kb) are on the left.
Table 1
Transfer of [14C]Neu5Ac to prothrombin and transferrin
Time (h) Protein-bound [14C]Neu5Ac (cpm)
prothrombin asialoprothrombin transferrin asialotransferrin
2 292 3856 428 994
4 657 9016 341 1885
The assay was performed as in Fig. 2A.
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transported to the cell wall during the assay by omitting so-
dium azide and adding glucose to the reaction mixture, 14C-
sialylation of asialofetuin doubled (Fig. 1B, open circles).
When both DTT and glucose were present, 14C-sialylation
was further increased (Fig. 2B, open squares). Also desialyl-
ated prothrombin (MW 73.6 kDa) and transferrin (MW 79.6
kDa) were 14C-sialylated (Table 1). The di¡erences in the
e⁄ciency of 14C-sialylation re£ect at least partly di¡erences
in the number of acceptor sites [21,22]. Fusion of ST3Ne to
the Hsp150v fragment was essential for activity and secretion
competence. When ST3Ne was linked directly to the Hsp150
signal peptide (strain H771), only little intracellular activity
was found (Fig. 2), although the HSP150v-ST3Ne and
ST3Ne genes were expressed at similar levels, as shown by
Northern analysis (insert).
3.2. E⁄ciency of sialylation
Next the degree of protein sialylation was quantitated.
Asialofetuin and saturating concentrations of unlabeled
CMP-Neu5Ac were incubated with H626 cells. Thereafter
the N-glycans of fetuin were released by N-glycosidase F di-
gestion and analyzed by MALDI-TOF mass spectrometry. In
4 h 31.7% of the terminal galactose residues were sialylated
(Fig. 3A,B). When a parallel cell suspension was pelleted after
the 4 h incubation, and the supernatant incubated for another
4 h with fresh yeast cells and CMP-Neu5Ac, 55.3% of the
galactose residues were sialylated (Fig. 3C). Thus, both asia-
loglycoproteins and partially sialylated proteins could be sial-
ylated. After 16 h, 61.3% of the galactose residues of fetuin,
and 41.5% of those of asialotransferrin were sialylated (not
shown). Fetuin, prothrombin and transferrin were subjected
to CD spectroscopy before and after desialylation. The spec-
tra of the sialylated and desialylated proteins were superim-
posable in all three cases (data not shown), suggesting that
proteins with native conformations could reach the cell wall-
borne ST3N activity.
3.3. Kinetic properties of Hsp150v-ST3Ne
Finally we compared the kinetic properties of yeast cell wall
Hsp150v-ST3Ne and recombinant ST3Ne produced in insect
cells. The Km values for asialofetuin, lacto-N-tetraose and N-
acetyllactosamine were similar (Table 2A). The relative ratios
Vmax/Km demonstrated that both enzyme preparations pre-
ferred lacto-N-tetraose (type 1: GalL1-3GlcNAc) over N-ace-
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Fig. 3. MALDI-TOF mass spectra of the N-glycans. Oligosaccha-
rides liberated from asialofetuin (A), or from asialofetuin incubated
for 4 h (B) or 8 h (C) with H626 cells. In A, signals were assigned
to non-sialylated triantennary glycans (m/z 2008, [M+H] ; m/z
2030, [M+Na]) and non-sialylated biantennary glycans (m/z 1665,
[M+Na]). In B and C, monosialylated biantennary (m/z 1956,
[M+Na] ; m/z 1978, [M-H+2Na]) ; monosialylated triantennary
(m/z 2321, [M+Na] ; m/z 2343, [M-H+2Na]), disialylated trianten-
nary (m/z 2612, [M+Na] ; m/z 2634, [M-H+2Na] ; m/z 2656, [M-
2H+3Na]) and trisialylated triantennary glycans (m/z 2903,
[M+Na] ; m/z 2925, [M-H+2Na]) were detected. The asterisk des-
ignates matrix adducts typical for this mode of analysis [16].
Table 2
Kinetic parameters of various ST3N preparations
Km (WM)
asialofetuin lacto-N-tetraose N-acetyllactosamine
A
Hsp150v-ST3Ne 42.7 (5.8) 51.0 (100) 717.7 (5.9)
rST3Ne 34.4 (10.9) 43.0 (100) 1014 (11.3)
CMP-Neu5Ac Reference
B
Hsp150v-ST3Ne 55 this work
rST3Ne 74.1 [24]
ST3N 57.3 [25]
CMP-Neu5Ac (A) or lacto-N-tetraose (B) was available in saturating concentrations. In B, varying concentrations of CMP-Neu5Ac up to 10 mM
were mixed with a constant amount of CMP-[14C]Neu5Ac. Enzyme preparations: Hsp150-ST3Ne in the wall of yeast cells ; recombinant ST3Ne
from insect cells (rST3Ne) ; authentic ST3N from rat liver. Figures in parentheses are the relative Vmax/Km values for the indicated substrates
(highest value is 100).
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tyllactosamine and asialofetuin (type 2: GalL1-4GlcNAc)
(Table 2A). The Km value of Hsp150v-ST3Ne for CMP-
Neu5Ac was similar to those reported for recombinant
ST3Ne from insect cells and authentic ST3N (Table 2B). A
1 l overnight culture containing 18 g (dry weight) of yeast cells
contained 117 mU of ST3N activity (lacto-N-tetraose as ac-
ceptor).
4. Discussion
We show here that unsialylated and undersialylated N-gly-
cosylated proteins with apparently native conformations could
be sialylated by incubating them with whole living recombi-
nant yeast cells harboring the rat liver K2,3-sialyltransferase
ectodomain (ST3Ne) fusion protein (Hsp150v-ST3Ne) in the
cell wall. Proper folding of ST3Ne and its intracellular trans-
port from the ER to the cell surface required the yeast-derived
polypeptide Hsp150v. ST3Ne as such acquired an enzymati-
cally inactive secretion-incompetent conformation, whereas
the fusion protein was readily secreted and its kinetic proper-
ties were similar to those of isolated rat liver ST3N and re-
combinant ST3Ne produced in insect cells. The Hsp150v pol-
ypeptide may have a chaperone-like activity, or attract
chaperones which assist folding of heterologous fusion part-
ners in the yeast ER [19,20]. Hsp150v-ST3Ne was tightly
bound to the cell wall covering the plasma membrane of yeast
cells. Binding appears to be due to the ST3Ne portion, be-
cause several other Hsp150v fusion proteins, the Hsp150v
fragment alone and full length authentic Hsp150 are secreted
to the culture medium [19,20,26]. Our recombinant yeast
strain provides an inexpensive and self-perpetuating source
of ST3N activity to complement sialylation of recombinant
proteins, as well as for sialylation of oligosaccharides. Due
to immobilization to the cell wall, the recombinant sialyltrans-
ferase needs not to be puri¢ed for use, and separation of the
product from the transferase occurs simply by pelleting the
cells.
The protein glycosylation machinery of insect cells is less
complex than that of mammalian cells, and this has been a
serious limitation for large-scale production of therapeutic
proteins in cultured insect cells [27]. The most frequent types
of N-glycans on proteins from cultured insect cells are of the
high mannose types with 3^9 mannose residues [4]. The most
developed N-glycan synthesized by Spodoptera frugiperda
(Sf9) cells appears to be Man3GlcNAc2 with at least one N-
acetylglucosamine residue linked to the mannose residues and
fucose to the chitobiose [28,29]. Interestingly, a subclone of
Estigmena acrea cells (Ea4) was able to galactosylate the N-
glycans of human interferon Q, though incompletely [28].
Thus, Ea4 cells appear to possess most enzymes required for
mammalian-type complex N-glycosylation, except sialyltrans-
ferases. If e⁄cient terminal N-acetylglucosaminylation and
galactosylation is achieved by clonal selection and/or express-
ing the appropriate mammalian glycosyltransferases, in vitro
sialylation of insect cell-derived recombinant proteins for ther-
apeutic use by our recombinant yeast cells should be a feasible
approach.
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